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mmol), 2× 10 -4 U of adenylate kinase and 0.5 mM AMP (or the 
Abstract The substrate and inhibitory properties of modified tested nucleotide). For evaluation of inhibitory properties, variable 
nucleutides with respect o adenylate kinase from rabbit muscles, amounts of modified nucleotides were added. 
human placenta and Escherichia coli were studied. A number of Measurement of the reverse reaction [2ADP ~ ATP+AMP] rate 
5'-hydrogenphosphonates and 5'-fluorophosphates of modified was performed in an incubation mixture (20 gl) containing 25 mM 
nucleotides were shown to inhibit the phosphorylation reaction Tris-HC1 (pH 7.7 at 37°C), 5 mM MgC12 , 0.05 mM [I]-32P]ADP (30 
catalyzed by these enzymes. A clear difference between Ci/mmol), 2 mM glucose, 2× 10 -4 U of adenylate kinase, 10 -4 U of 
phosphonates of 3'-deoxyribonucleotides and the corresponding hexokinase and, where necessary, the appropriate amount of the in- 
ribo- and 2',3'-dideoxyribonucleotides was found. 3'-Azido-2',3'- hibitor. Samples (1 gl) were taken from the incubation mixture at 10-min 
dideoxythymidine and its phosphorus derivatives did not inhibit intervals and analyzed by TLC on polyethyleneimine-cellulose plat s 
the adenylate kinase reaction, in 0.5 M KH2PO4. The TLC plates were dried and radioautographed. 
Each spot was cut according to the radioautograph and the radio- 
Key words: Adenylate kinase; Modified nucleotide; activity was counted in a scintillation counter by means of the Cher- 
Phosphorylation; Substrate specificity enkov effect. 
3. Results and discussion 
1. Introduction 
Substrate and inhibitory properties of modified nucleotides 
High anti-HIV activity of 5'-hydrogenphosphonates [1-7] I - IV were evaluated in the reactions catalyzed by adenylate 
and 5'-fluorophosphates [8 10] of modified nucleotides in kinase from rabbit muscles, E. cob and human placenta. The 
virus-infected cell cultures has recently been reported. Their latter two enzymes were only partly purified to a specific ac- 
metabolism, however, has been investigated inadequately, and tivity of 0.2 U/mg [13], but were free of phosphatase, non- 
the data are contradictory. For  instance, 5'-hydrogenphos- specific ATPase and other NMP-kinase impurities. 
phonates of modified thymidine are stable in the presence of Only phosphates Ia- I I Ia  were phosphorylated in the pres- 
phosphatases [11] whereas in human blood serum they are ence of all three kinases. The phosphorylation rates for IIa 
dephosphorylated, although 10-100 times slower than the cor- and II Ia vs. that for AMP (Ia) are shown in Table 1. None of 
responding 5'-phosphates [12]. Furthermore, it was recently the phosphonates (Ib IIIb) and fluorophosphates ( IcqI Ic)  
reported that 3'-azido-3'-deoxythymidine (AZT) inhibited was phosphorylated, but most exhibited inhibitory activity 
the reaction [2ADP ~ ATP+AMP] catalyzed by adenylate ki- when added to the reaction mixture. Fig. 1 demonstrates the 
nase from rabbit muscle and did not affect the reverse reaction reaction rates catalyzed by adenylate kinase from human pla- 
[16]. This result seems unusual as kinases are known to be centa at various concentrations of the inhibitors. The inhibitor 
specific towards the nature of the nucleic base in substrate to AMP concentration ratios at which the reaction rate is 
molecule, decreased by 50% are listed in Table 2. 
We present here data on the phosphorylation of a series of Since the inhibitory effect was seen only if the inhibitors 
nucleoside 5'-hydrogenphosphonates and 5'-fluorophosphates were added in a large excess with respect o AMP and, corre- 
( Ia-c)-( IVa-c) (Scheme 1) as well as AZT and its derivatives spondingly, in still larger excess with respect o ATP, it was 
by adenylate kinase from different sources, not improbable that the  inhibition could be caused by an 
impurity that is undetectable by the usual analytic methods. 
2. Materials and methods To exclude this possibility, we carried out experiments using 
[U-I4C]AMP. The reaction mixture contained 0.05 mM [U- 
Adenylate kinase from rabbit muscles was purchased from Sigma; 14C]AMP with a specific activity of 585 Ci/mol and ATP was 
enzyme from E. coli and from human placenta was isolated according in excess with respect o both AMP and the substances tested. 
to Rikhter et al. [13], with slight modifications. Yeast hexokinase was 
obtained from Fluka. The synthesis of compounds Ib,c [14], IIb,c The results were in a good agreement with those obtained by 
[6,9], IIIa~: [6,9], IVa,c [15], IVb [1] was carried out as described, the standard procedure (data not shown). 
Other nucleotides were from Sigma. Fig. 2 shows the results of examination of the inhibitory 
Kinetic assay for the reaction [ATP+AMP ~ 2ADP] was carried properties of AZT (IVa). The reaction proceeded from ADP 
out at 37°C in an incubation mixture (20 gl) containing 25 mM 
to AMP+ATP in the presence of hexokinase to make it irre- Tris-HC1 (pH 7.7), 5 mM MgC12 , 0.05 mM [7-32p]ATP (30 Ci/ 
versible. No inhibitory effect of AZT could be seen. The same 
*Corresponding author. Fax. 7-095-1351405, results were obtained with the two other tested adenylate ki- 
E-mail chernov@imb.imb.ac.ru nases (data not shown). 
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The data obtained emonstrated that only adenylates with 
Fig. 1. Dependence of AMP phosphorylation rate (v) catalyzed by 
the unmodified phosphate group (Ia-II Ia) were phosphory- human placental adenylate kinase on inhibitor (Inh) concentration; 
luted by all adenylate kinases. AMP and 2',3'-dideoxyribo- v0, reaction rate in the absence of inhibitor. 
adenosine 5'-phosphate (IIIa) were found to be better sub- 
strates than dAMP (Table 1). A similar relationship was 
demonstrated for the inhibitory properties of ribo-, 2'-deoxy- nases, nor compete with natural 5'-nucleotides [17]. Since 
ribo- and 2',3'-dideoxyribohydrogenphosphonates (Ib-I I Ib) compounds I I Ib~ are not phosphorylated in the presence of 
and fluorophosphates (Ic-IIIc). human adenylate kinase, there must be another metabolic 
2'-Deoxyriboadenylates (lib,c) did not inhibit the reaction pathway for developing their anti-HIV activity. 
under study up to a 100-fold molar excess with respect to Our results on inhibition of adenylate kinases by AZT (IVa) 
AMP (Table 2). or its derivatives (IVa,b) disagree with the data of Barile et al. 
Thus, the modified 3'-deoxyriboadenylates (IIa~c) clearly [16]. All the studied enzymes were not inhibited by com- 
differ as substrates and inhibitors from the ribo (Ia-c) and pounds IVa-c up to a 100-fold excess with respect o AMP 
2',3'-dideoxyribo (IIIa-c) analogs. The effect might be due or ADP concentration, without regard to the reaction direc- 
to different interactions with the enzyme of 'symmetric' tion. 
(ribo- and 2',3'-dideoxyribo-) and 'asymmetric' (3'-deoxyri- Thus, the tested adenylate kinases exhibit high specificity 
bo-) glycones, towards the structure of the phosphorus-containing fragment 
The results obtained suggest hat the structure of the phos- in the substrate molecule. This property can be of use for the 
phate residue in adenylates i crucial for the phosphorylation design of new antiviral agents targeted at DNA synthesis cat- 
catalyzed by adenylate kinases. These data agree with those alyzed by viral DNA polymerases, particularly reverse tran- 
for nucleoside 5'-fluoromethylphosphonates, which could scriptases. The latter are known to display reduced specificity 
neither be phosphorylated by human cellular nucleotidyl ki- towards dNTP modified at the phosphorus atom and can 
Table 1 
Ratio of nucleoside phosphate phosphorylation rate to that for 
AMP 
Substrate Adenylate kinase 
Rabbit muscle E. eoli Human placenta 
lla 0.75 0.4 0.53 ~ A [ 32 P]  glucose-6-phosphate 
Ilia 0.95 0.9 0.95 
Table 2 [~ 
Inhibition of AMP pbosphorylation bynucleoside derivatives 
Compound [Inh]~0/[AMP] 
Rabbit muscle E. coli Human placenta 
IIb - - - 
IIIb 25 20 20 . . . . . .  " " ' - - '~"  IY - 32r ' lA l l t "  
Ic 20 > 50 15 
IIc - - 
IIIc >50 >50 >50 1 2 3 4 5 
IVa~ - Fig. 2. Phosphorylation i  the presence of IVa (AZT) catalyzed by 
[Inh]50/[AMP] is the ratio of inhibitor and AMP concentrations at adenylate kinase from rabbit muscles. For details of the reaction 
which 50% inhibition was observed; '- '  indicates that inhibition was conditions, see Section 2; I, without hexokinase and AZT; 2, 
not found up to a 100-fold molar excess of the compound tested with without AZT (reference); 3, 4 mM AZT; 4, 10 mM AZT; 5, 
respect o AMP. [13-32P]ADP. 
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